Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 6: “Number Needed to Treat” to Prevent One Case.

Slides:



Advertisements
Similar presentations
Basic statistics: a survival guide
Advertisements

Comparing Two Proportions (p1 vs. p2)
What role should probabilistic sensitivity analysis play in SMC decision making? Andrew Briggs, DPhil University of Oxford.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 5: Reporting Subgroup Results.
Confidence Intervals © Scott Evans, Ph.D..
Point estimation, interval estimation
Statistics By Z S Chaudry. Why do I need to know about statistics ? Tested in AKT To understand Journal articles and research papers.
Inferences About Process Quality
Statistics for Health Care
Review for Exam 2 Some important themes from Chapters 6-9 Chap. 6. Significance Tests Chap. 7: Comparing Two Groups Chap. 8: Contingency Tables (Categorical.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Are the results valid? Was the validity of the included studies appraised?
Statistics for clinical research An introductory course.
HSRP 734: Advanced Statistical Methods July 10, 2008.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 4: Taking Risks and Playing the Odds: OR vs.
Biostatistics in Clinical Research Peter D. Christenson Biostatistician January 12, 2005IMSD U*STAR RISE.
Inference for a Single Population Proportion (p).
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 5: Analysis Issues in Large Observational Studies.
6.1 - One Sample One Sample  Mean μ, Variance σ 2, Proportion π Two Samples Two Samples  Means, Variances, Proportions μ 1 vs. μ 2.
Research Skills Basic understanding of P values and Confidence limits CHE Level 5 March 2014 Sian Moss.
Assessing Survival: Cox Proportional Hazards Model
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 2: Diagnostic Classification.
N318b Winter 2002 Nursing Statistics Hypothesis and Inference tests, Type I and II errors, p-values, Confidence Intervals Lecture 5.
Biostatistics in Practice Peter D. Christenson Biostatistician LABioMed.org /Biostat Session 6: Case Study.
01/20151 EPI 5344: Survival Analysis in Epidemiology Interpretation of Models March 17, 2015 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive.
How to Analyze Therapy in the Medical Literature (part 2)
Effect Size Estimation in Fixed Factors Between-Groups ANOVA
Effect Size Estimation in Fixed Factors Between- Groups Anova.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Section Copyright © 2014, 2012, 2010 Pearson Education, Inc. Lecture Slides Elementary Statistics Twelfth Edition and the Triola Statistics Series.
Biostatistics Class 6 Hypothesis Testing: One-Sample Inference 2/29/2000.
HSRP 734: Advanced Statistical Methods July 17, 2008.
Biostatistics in Practice Peter D. Christenson Biostatistician LABioMed.org /Biostat Session 4: Study Size and Power.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 4: Study Size and Power.
Chapter 5 Parameter estimation. What is sample inference? Distinguish between managerial & financial accounting. Understand how managers can use accounting.
Which Treatment ? For a patient, 64-year-old male For a patient, 64-year-old male No HT, DM, Heart failure, LV dysfunction No HT, DM, Heart failure, LV.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 2: Summarization of Quantitative Information.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 6: Case Study.
Biostatistics Case Studies 2010 Peter D. Christenson Biostatistician Session 3: Clustering and Experimental Replicates.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 3: Testing Hypotheses.
Fall 2002Biostat Statistical Inference - Confidence Intervals General (1 -  ) Confidence Intervals: a random interval that will include a fixed.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 4: Study Size for Precision or Power.
Comparing Two Proportions. A new twist on some old ideas… When combining proportions we treat proportions and standard errors in much the same way as.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 1: Demonstrating Equivalence of Active Treatments:
Survival Analysis approach in evaluating the efficacy of ARV treatment in HIV patients at the Dr GM Hospital in Tshwane, GP of S. Africa Marcus Motshwane.
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 2: Correlation of Time Courses of Simultaneous.
Biostatistics Case Studies 2014 Youngju Pak Biostatistician Session 5: Survival Analysis Fundamentals.
Sample Size Determination
Compliance Original Study Design Randomised Surgical care Medical care.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 2: Aging and Survival.
Statistical significance using Confidence Intervals
1 Definitions In statistics, a hypothesis is a claim or statement about a property of a population. A hypothesis test is a standard procedure for testing.
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
SAMPLING DISTRIBUTION OF MEANS & PROPORTIONS. SAMPLING AND SAMPLING VARIATION Sample Knowledge of students No. of red blood cells in a person Length of.
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 3: Missing Data in Longitudinal Studies.
Biostatistics Case Studies 2009 Peter D. Christenson Biostatistician Session 2: Survival Analysis Fundamentals.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 1: Demonstrating Equivalence of Active Treatments:
2 3 انواع مطالعات توصيفي (Descriptive) تحليلي (Analytic) مداخله اي (Interventional) مشاهده اي ( Observational ) كارآزمايي باليني كارآزمايي اجتماعي كارآزمايي.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
HelpDesk Answers Synthesizing the Evidence
Sample Size Determination
ESTIMATION.
Confidence Intervals and p-values
Interpreting Basic Statistics
EBM – therapy Dr. Tina Dewi J , dr., SpOG
Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.
Presentation transcript:

Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 6: “Number Needed to Treat” to Prevent One Case

Case Study

Results

Main Figures for Results Studies in Glaucoma Subjects: Studies in Ocular Hypertensive Subjects:

Goals of this Session 1.Define “Number Needed to Treat” (NNT). 2.Show how to calculate NNT for published studies analyzed with methods for equal follow up for all subjects. 3.Show how to calculate NNT for published studies analyzed with survival (time-to-event) methods. 4.Reproduce NNT values for the case study. 5.Disadvantages of NNT.

NNT: Subjects Followed Equally NNT = the number of subjects who need to be treated in order to expect to prevent one case, relative to subjects not treated. Let p t = proportion of treated subjects who have the event in the fixed time period, and p c the proportion of control subjects with the event. The absolute risk reduction, ARR, is p c -p t. Since ARR is the proportion of treated subjects in whom events were prevented, NNT=1/ARR. 95% CI for NNT is 1/A U to 1/A L, where (A L,A U ) is the 95% CI for ARR.

Examples: Subjects Followed Equally NPcPc PtPt ScSc StSt ARRNNTALAL AUAU NNT 95%CI to to to to to to 2.8 S t = treated proportion surviving, i.e., w/o event = 1-P t. A L = ARR – 1.96*Standard Error (ARR) = ARR – 1.96*square root [P c *S c /N + P t *S t /N].

Comments: Subjects Followed Equally 1.NNT (and ARR) refer only to the fixed follow up time for all subjects. 2.NNT is based on risk difference, not risk ratio (RR). Note that RR = 2.0 for all of the previous examples. 3.CIs can be obtained from reported Ps (or Ss) and Ns using formula on previous slide. 4.Cannot obtain NNT (or ARR) from RR only. Need risk or survival (one of P c, P t, S c, or S t ). Usually underlying risk Pc for target population is used.

Generalization to Unequal Subject Follow Up 1.NNT is still specific to a particular specified time of follow up. 2.NNT is still 1/ARR = 1/(S t -S c ), but S t and S c are found from survival methods: either Kaplan-Meier or Cox regression. 3.To find NNT from a published paper, we need either: S t and S c, and for a CI on NNT, either their standard errors (which could be found from their CIs) or the numbers of subjects at risk at the F/U time (which are often in graphs). The hazard ratio (HR) and Sc (or St), and for a CI on NNT, the standard error of HR (which could be found from its CI). This is the typical way that results are reported.

NNT Results for the Case Study

Reproduce NNT for the Case Study Studies in Ocular Hypertensive Subjects: Hazard Ratio HR = 0.56 (95% CI: 0.39 to 0.81). S c is assumed to be The key to obtaining ARR, and thus NNT, is that the Cox regression model assumes that S t = [S c ] HR. Here, S t = [0.80] 0.56 = Thus, ARR = = NNT = 1/ARR = 1/ = 12.12, reported as 12. A U = [0.80]0.39 – 0.80 = = A L = [0.80]0.81 – 0.80 = = % CI for NNT is 1/A U to 1/A L = 1/ to 1/ = 8.6 to 28.9, reported as 9 to 29.

Reproduce NNT for the Case Study Studies in Glaucoma Subjects: Hazard Ratio HR = 0.65 (95% CI: 0.49 to 0.87). S c is assumed to be The key to obtaining ARR, and thus NNT, is that the Cox regression model assumes that S t = [S c ] HR. Here, S t = [0.40] 0.65 = Thus, ARR = = NNT = 1/ARR = 1/ = 6.61, reported as 7. A U = [0.40]0.49 – 0.40 = = A L = [0.40]0.87 – 0.40 = = % CI for NNT is 1/A U to 1/A L = 1/ to 1/ = 4.2 to 19.8, reported as 4 to 20.

Disadvantages of NNT: Heterogeneity Scaling: NNT differs for subpopulations with different underlying risk, but equal RR. Questionable use for meta analysis summary overall measure since underlying risk may differ among studies. Could find NNT for studies separately and give range of NNTs. In a single study, subgroups may also have differing underlying risk, so again separate NNTs may be more useful.

Disadvantages of NNT: Non-Significant Treatment Effect If p<0.05 for treatment effect, then the 95% CI for NNT contains negative numbers; e.g., need to treat between -18 and 8 subjects from the Kamal study! Negative values refer to NNT for harm. Positive values refer to NNT for benefit. Some have suggested an interpretation using the fact that treatment effect zero corresponds to ∞ subjects. In my opinion, NNT should not be used here: if the CI is narrow and contains 0, we are sure there is no effect, so NNT is irrelevant, and if the CI is wide, NNT is not useful anyway.

Other References Original NNT suggestion: Cook et al. BMJ 1995; 310: More detail on NNT in survival analyses: Altman et al. BMJ 1999; 319: Negative NNT confidence interval issues: Altman et al. BMJ 1998; 317:

Personal Conclusions NNT can be useful way to express the effort needed (many treated subjects) for treatments with moderate relative risks and small underlying risk. Limit NNT to groups that are homogeneous for underlying risk, and to treatments that show significant effects.